doctype html
html(lang="en")
	head
		- var page = { home: "", rasStory: "is-current", firstLine: "", thirdLine: "", administration: "", patientProfiles: "", access: "", generic: "", paidHome: "" };
		include includes/_head.pug
		title RAS Story

	body
		form
			.pageWrap
				include includes/_notifyMain.pug
				include includes/_headerMain.pug
				main
					.hero(style="background-image:url(img/content-images/hero.png)")
						.hero-inner
							.hero-copy
								span.hero-zone1 In the first-line treatment of mCRC
									sup 1 
								span.hero-zone2.mb-0 Biomarker identification can provide critical information
									sup 2
					section#krasNras.py-12
						.container
							h2.colorBrandBlue
								|
								em KRAS 
								|  and 
								em NRAS
								|  are part of the 
								em RAS 
								| family of oncogenes
								sup 1 
							.row
								.col-md-5.colorGrayDarker.pt-md-10
									p
										em RAS
										|  status definitions
										sup 2
										|:
									ul.list--spaced
										li 
											strong #[em RAS] mutation negative
											|, or wild type (WT), means the #[em RAS] genes (#[em KRAS] and #[em NRAS]) do not have mutations
										li 
											strong #[em RAS] mutation negative
											|, or mutant type (MT), means that at least one of the #[em RAS] genes (#[em KRAS] or #[em NRAS]) contains a mutation that affects its function
								.col-md-7
									figure
										img(src='img/content-images/kras-exor-2-analysis-sm.svg').d-md-none
										img(src='img/content-images/kras-exor-2-analysis-lg.svg').d-none.d-md-block.mt-10
							p.reference mCRC = metastatic colorectal cancer; MT = mutant type; WT = wild type.
					section#wtRas.py-12.fillGradientBlue
						.container
							.row
								.col-md-9
									p.colorBrandOrangeLight.textLg
										| Don't let patients with WT 
										em RAS
										span.pl-1 *
										|  mCRC miss a chance for personalized treatment
										sup 1 
									h2.fontDefault.h1
										| The importance of biomarker identification
									hr.hr--fade
									h3.h2.py-3
										|Identification of patients with WT 
										em.px-1 RAS 
										| mCRC can help determine appropriate treatment options
										sup 1
									figure.mb-5
										img(src='img/content-images/prime-population-sm.svg').shadow.d-md-none
										img(src='img/content-images/prime-population-lg.svg').shadow.d-none.d-md-block
							h3.h2.mb-5
								| Patients with MT 
								em RAS 
								|  tumors should not be treated with Vectibix
								sup &reg;1

							p Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines#[sup &reg;]) for Colon Cancer V2.2017. &copy; National Comprehensive Cancer Network, Inc 2017. All rights reserved. Accessed May 11, 2017. To view the most recent and complete version of the guideline, go online to #[a(href='https://www.nccn.org/') NCCN.org]. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 


							blockquote.my-5
								.tr
								| "All patients with metastatic colorectal cancer should have tumor tissue genotyped for 
								em RAS 
								|(
								em KRAS
								|  and 
								em NRAS
								|) mutations" &mdash;NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
								sup &reg;
								| ) for Colon Cancer
								sup 3
							p.reference
								span.pullSup *
									| Defined as wild type in both 
									em KRAS 
									| and 
									em NRAS.
									sup 1
									br
									| mCRC = metastatic colorectal cancer; MT = mutant type; NCCN = National Comprehensive Cancer Network; WT = wild type.
				include includes/_notifyTray.pug
				.container
					.inlined.reference
						h2.h5 References:
						ol
							li
								|  Vectibix
								sup &reg;
								|  (panitumumab) prescribing information, Amgen; 6/2017. 
							li
								|  Douillard J-Y, Oliner KS, Siena S, et al. Panitumumabâ€“FOLFOX4 treatment and 
								em RAS
								|  mutations in colorectal cancer. 
								em N Engl J Med.
								|  2013;369(11):1023-1034. 
							li
								|  Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
								sup &reg;
								| ) for Colon Cancer V2.2017. &copy;National Comprehensive Cancer Network, Inc 2017. All rights reserved. Accessed April 21, 2017. To view the most recent and complete version of the guideline, go online to NCCN.org. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
				include includes/_footerMain.pug

